Incident Diabetic Retinopathy after Adjunctive Tirzepatide Treatment for 1 Year in Adults with Type 1 Diabetes
Authors' conclusion
OW/obese individuals with T1D treated with off-label tirzepatide developed DR similar to controls.
Study context
- Population
- Overweight/obese adults with T1D; mean diabetes duration 26.2 years (cases) and 28.0 years (controls); most using AID
- Participants
- 106 vs 85
- Exposure
- Adjunctive tirzepatide vs no tirzepatide
- Casesn = 106
- Controlsn = 85reference
- Outcome
- Incidence of DR and diabetic macular edema (DME) in individuals without baseline eye disease
- Follow-up
- 6-24 months
Methodological detailsretrospective chart review, matched by age, sex and BMI
- Retrospective chart review
- Matched by age, sex and BMI
Main finding
As reported in the abstract
New-onset DR · mean follow-up 11.7 (cases) and 15.3 (controls) months
| Group | Value | Denominator |
|---|---|---|
| Cases | 25.6% | 39 |
| Controls | 29.2% | 24 |
Value
Cases25.6%
Controls29.2%
Denominator
Cases39
Controls24
Observational data: associations, not effects.
Further findings
Baseline DR and/or DME
| Outcome | P value |
|---|---|
| Incident DR by rapid HbA1c decline (≥0.5% within 6 months), cases and controls combinedRapid HbA1c decline vs No rapid decline | P = 0.048 |
- Incident diabetic retinopathy (DR) by rapid hemoglobin A1C (HbA1c) decline (≥0.5% within 6 months), cases and controls combined: Rapid HbA1c decline 39.3% · denominator 28
- Incident DR by rapid HbA1c decline (≥0.5% within 6 months), cases and controls combined: No rapid decline 17.1% · denominator 35
HbA1c · within 6 months
- Mean HbA1c improved within 6 months and remained stable for cases, but was unchanged for controls
- P < 0.001
Progression of eye disease in those with baseline DR
- Eye disease remained stable at follow-up for most individuals (cases and controls)
Original publication
Incident Diabetic Retinopathy after Adjunctive Tirzepatide Treatment for 1 Year in Adults with Type 1 Diabetes. Diabetes Technol Ther. Published 14 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →